Discovery of novel inhibitors of Bcl-xL using multiple high-throughput screening platforms

Analytical Biochemistry

Volumn 328, Issue 2, 2004, Pages 131-138

  Qian, Jie ^a   Voorbach, Martin J ^a   Huth, Jeffrey R ^a   Coen, Michael L ^a   Zhang, Haichao ^a   Ng, Shi Chung ^a   Comess, Kenneth M ^a   Petros, Andrew M ^a   Rosenberg, Saul H ^a   Warrior, Usha ^a   Burns, David J ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Affinity selection mass spectrometry; Apoptosis; Bcl xL; Fluorescence polarization assay

Indexed keywords

CELL DEATH; DIAGNOSIS; DRUG PRODUCTS; FLUORESCENCE; MAGNETIC RESONANCE; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MIXTURES; POLARIZATION; PROTEINS;

ACTIVITY ASSAYS; AFFINITY SELECTION; APOPTOTIC PROCESS; BCL-XL; DRUG COMPOUNDS; ELECTROSPRAY MASS SPECTROMETRY; FLUORESCENCE POLARIZATION; HIGH THROUGHPUT SCREENING;

BINDERS;

PROTEIN BCL XL; PROTEIN BCL XL INHIBITOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DRUG CLASSIFICATION; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; FLOW INJECTION ANALYSIS; FLUORESCENCE POLARIZATION; HIGH THROUGHPUT SCREENING; IC 50; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN FUNCTION; SCREENING TEST; ULTRAFILTRATION;

EID: 11144354792     PISSN: 00032697     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ab.2003.12.034     Document Type: Article

References (30)

1. Wei M.C., Zong W.X., Cheng E.H., Lindsten T., Panoutsakopoulou V., Ross A.J., Roth K.A., MacGregor G.R., Thompson C.B., Korsmeyer S.J. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 292:2001;727-730
2. Cheng E.H., Wei M.C., Weiler S., Flavell R.A., Mak T.W., Lindsten T., Korsmeyer S.J. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell. 8:2001;705-711
3. Yang E., Zha J., Jockel J., Boise L.H., Thompson C.B., Korsmeyer S.J. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell. 80:1995;285-291
4. Yin X.M., Oltvai Z.N., Korsmeyer S.J. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature. 369:1994;321-323
5. Petros A.M., Nettesheim D.G., Wang Y., Olejniczak E.T., Meadows R.P., Mack J., Swift K., Matayoshi E.D., Zhang H., Thompson C.B., Fesik S.W. Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci. 9:2000;2528-2534
6. Petros A.M., Medek A., Nettesheim D.G., Kim D.H., Yoon H.S., Swift K., Matayoshi E.D., Oltersdorf T., Fesik S.W. Solution structure of the antiapoptotic protein bcl-2. Proc. Natl. Acad. Sci. USA. 98:2001;3012-3017
7. Sattler M., Liang H., Nettesheim D., Meadows R.P., Harlan J.E., Eberstadt M., Yoon H.S., Shuker S.B., Chang B.S., Minn A.J., Thompson C.B., Fesik S.W. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science. 275:1997;983-986
8. Muchmore S.W., Sattler M., Liang H., Meadows R.P., Harlan J.E., Yoon H.S., Nettesheim D., Chang B.S., Thompson C.B., Wong S.L., Ng S.L., Fesik S.W. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature. 381:1996;335-341
9. Huang Q., Petros A.M., Virgin H.W., Fesik S.W., Olejniczak E.T. Solution structure of a Bcl-2 homolog from Kaposi sarcoma virus. Proc. Natl. Acad. Sci. USA. 99:2002;3428-3433
10. Losonczi J.A., Olejniczak E.T., Betz S.F., Harlan J.E., Mack J., Fesik S.W. NMR studies of the anti-apoptotic protein Bcl-xL in micelles. Biochemistry. 39:2000;11024-11033
11. Kelekar A., Chang B.S., Harlan J.E., Fesik S.W., Thompson C.B. Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-XL. Mol. Cell Biol. 17:1997;7040-7046
12. Ottilie S., Diaz J.L., Horne W., Chang J., Wang Y., Wilson G., Chang S., Weeks S., Fritz L.C., Oltersdorf T. Dimerization properties of human BAD. Identification of a BH-3 domain and analysis of its binding to mutant BCL-2 and BCL-XL proteins. J. Biol. Chem. 272:1997;30866-30872
13. Minn A.J., Velez P., Schendel S.L., Liang H., Muchmore S.W., Fesik S.W., Fill M., Thompson C.B. Bcl-x(L) forms an ion channel in synthetic lipid membranes. Nature. 385:1997;353-357
14. Minn A.J., Kettlun C.S., Liang H., Kelekar A., Vander Heiden M.G., Chang B.S., Fesik S.W., Fill M., Thompson C.B. Bcl-xL regulates apoptosis by heterodimerization-dependent and -independent mechanisms. EMBO J. 18:1999;632-643
15. Reed J.C. Mechanisms of apoptosis avoidance in cancer. Curr. Opin. Oncol. 11:1999;68-75
16. Kusenda J. Bcl-2 family proteins and leukemia. Minireview. Neoplasma. 45:1998;117-122
17. Minn A.J., Rudin C.M., Boise L.H., Thompson C.B. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood. 86:1995;1903-1910
18. Basu A., Haldar S. The relationship between Bcl2, Bax, and p53: consequences for cell cycle progression and cell death. Mol. Hum. Reprod. 4:1998;1099-1109
19. Itoh M., Noutomi T., Chiba H., Mizuguchi J. Bcl-xL antisense treatment sensitizes Bcl-xL-overexpressing squamous cell carcinoma cells to carboplatin. Oral Oncol. 38:2002;752-756
20. G.R. He, K.Y. Zhou, K.R. Cai, T. Liang, C.W. He, Y.F. Zhang, [Apoptotic effect of bcl-XL antisense oligodeoxynucleotide mediated by lipofectin on cell strain CNE-2Z], Ai Zheng 22 (2003) 11-15
21. Jiang Z., Zheng X., Rich K.M. Down-regulation of Bcl-2 and Bcl-xL expression with bispecific antisense treatment in glioblastoma cell lines induce cell death. J. Neurochem. 84:2003;273-281
22. Gleave M., Miyake H., Zangemeister-Wittke U., Jansen B. Antisense therapy: current status in prostate cancer and other malignancies. Cancer Metastasis Rev. 21:2002;79-92
23. Jansen B., Schlagbauer-Wadl H., Brown B.D., Bryan R.N., van Elsas A., Muller M., Wolff K., Eichler H.G., Pehamberger H. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med. 4:1998;232-234
24. Simoes-Wust A.P., Schurpf T., Hall J., Stahel R.A., Zangemeister-Wittke U. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel, and cyclophosphamide. Breast Cancer Res. Treat. 76:2002;157-166
25. Mercatante D.R., Mohler J.L., Kole R. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J. Biol. Chem. 277:2002;49374-49382
26. Zhang H., Nimmer P., Rosenberg S.H., Ng S.C., Joseph M. Development of a high-throughput fluorescence polarization assay for Bcl-x(L). Anal. Biochem. 307:2002;70-75
27. Degterev A., Lugovskoy A., Cardone M., Mulley B., Wagner G., Mitchison T., Yuan J. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat. Cell Biol. 3:2001;173-182
28. Gopalakrishnan S.M., Karvinen J., Kofron J.L., Burns D.J., Warrior U. Application of micro arrayed compound screening (microARCS) to identify inhibitors of caspase-3. J. Biomol. Screen. 7:2002;317-323
29. Zhang J.H., Chung T.D., Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high- throughput screening assays. J. Biomol. Screen. 4:1999;67-73
30. Banks P., Harvey M. Considerations for using fluorescence polarization in the screening of G protein-coupled receptors. J. Biomol. Screen. 7:2002;111-117